to study the effect of the changes on the characteristics of the output spectra. Thus, we expected that many differences between the research data sets would exist due to the differences in the experimental design used to generate each data set.
The application of mass spectrometry to discover new cancer biomarkers is in its infancy. Many of these new markers are low-abundance proteins that exist as fragments associated with carrier proteins. Although reproducibility is key to the use of mass spectrometry for ion fi ngerprint analysis, the scientifi c community has yet to establish a common platform or standardized operating procedures that are necessary for intra-and inter-laboratory comparison. In an effort to assist others who are perfecting mass spectrometry platforms for profi ling, ongoing experimental data were posted for public consumption. An unintended consequence of unrestricted access to experimental data is the risk of inappropriate conclusions drawn and publicly disseminated that focus on the apparent ability by Zhu et al. to identify diagnostic signatures in one ovarian cancer experimental data set, which was posted on our website in April 2002. That set was able to accurately predict phenotypes in a second separate and independent data set, which was produced and posted in August 2002. On the basis of their own analysis of these two data sets, Baggerly et al. ( 1 ) claim that the diagnostic signatures reported by Zhu et al. are not accurate and conclude that reproducibility within the two posted data sets used in these studies has not been demonstrated. Baggerly et al. further generalize that between-set mass spectral reproducibility itself remains an open question and justify their conclusions as follows: 1) The case and control samples in the second data set could be separated by randomly selected values. 2) Some peaks that go up in one set go down in the second set.
3) The m/z features found by Zhu et al. appear to change in amplitude across the two experimental sets posted.
We are not surprised that Baggerly et al. found differences between our posted ovarian cancer studies data sets. Each data set that we have posted is generated from an experimental setting in which one or more of the parameters have been purposefully changed. Under classic experimental design, we held some parameters constant as we deliberately changed other parameters same type of chip surface, data set 8 -7 -02 was produced with a different and roboticized sample application method, with different washing and binding conditions, and with an entirely different, upgraded, low-resolution mass spectrometer. We would be surprised if the experimentally designed process changes between these two studies did not result in altered spectra. In fact, a goal of these experiments was to study the spectral alterations produced by changing the process! The experimental goals of the two study sets and the way the samples were processed were different. The goal of data set 4 -3 -02 was to evaluate the ability of a weak cation-exchange chip surface to generate mass spectral information that could be used to segregate case and control ovarian cancer samples. In contrast, the goal of data set 8 -7 -02 was to determine whether the betweenday total process variance was more or less than the variance between the case and control groups. For data set 8 -7 -02, case and control samples were run in separate batches on separate days and not commingled. We used protocols recommended by the Clinical and Laboratory Standards Institute (formerly NCCLS) to explore the individual sources of between-day spectral variation generated within a single batch or run, independent of differences in the phenotype of the samples themselves. Important and ongoing questions have been whether differences in sample collection between case patients and control subjects could contribute to analytical bias and whether qualitative differences could contribute to the source of variance within each phenotype. As with any unprocessed electronic signal, scalar changes in the relative intensity values, reported by mass spectrometry, can change dramatically from day to day. Consequently, investigators often use normalization procedures (e.g., dividing by total ion current or by maximum ion signal) that may correct for scalar differences. If the spectra are not normalized (and it appears that Baggerly et al. did not normalize the spectra for their analysis), it is likely that randomly chosen values would be able to separate the two phenotypes. The design of the experiment required that the cancer samples and control samples be run on separate days, thus generating scalar intensity differences across the two groups. The conclusion of Baggerly et al. that " systematic differences in spectra are more likely associated with procedural bias, such as incomplete randomization, that confounds our ability to recognize potentially reproducible biological factors " was expected, and so it inappropriately casts a negative view on a planned component of the experimental design of this study that investigated relative sources of process variance.
Need for Optimization and Protocol Standardization Before Analysis of Reproducibility
Certainly, the issue of reproducibility is of major importance to investigators evaluating and researching mass spectral profi les for disease detection. Nevertheless, a meaningful analysis of reproducibility requires communication between those producing the data (in this case, us) and those analyzing, or consuming, the data. Why is this communication necessary? Communication helps to ensure that data are being evaluated within the context of the experimental conditions used and the questions that were being asked when the data were produced ( 3 , 4 ) . Without such communication, data can be misinterpreted, unwarranted and overextended conclusions can be drawn, and misinformation can be spread. Unfortunately, we believe that this may be exactly what has happened here.
The discussion of experimental reproducibility is a key question to those attempting to use mass spectrometry for discovery or profi ling approaches. Although our own laboratory efforts are now emphasizing sequencing and characterization of the lowmolecular-weight biomarker candidates, we are also continuing to seek a better understanding of the sources of analytical and physical variability along the entire process (from sample collection to data generation). We and others in the fi eld have begun to develop appropriate quality control and quality assurance procedures to increase process stability. During this process, we have posted examples of our raw mass spectral data in the public domain, much of it experimental and not published in peer-reviewed journals. In fact, the two ovarian cancer data sets in question were not part of any publication. These postings are meant to provide the community an unbiased and transparent snapshot into our ongoing experimental research work and to further provide data sets for their own work, whatever that may be. As a consequence of the unrestricted Web access to multiple data sets, many investigators have downloaded the data and analyzed them.
In hopes of enabling the clearest understanding of our data, we have annotated our Web-posted data in the hope that they will be analyzed appropriately and will be judged only in the context of the data collection experiment. We are hopeful that processes and platforms will evolve to a point where mass spectral pattern analysis can be used for routine diagnostics and commercialized after rigorous validation and scientifi c publication after peer review. Academic consortium groups, such as the National Cancer Institute's Early Detection Research Network, have reported very promising initial results for the systematic evaluation of reproducibility of mass spectral profi ling for prostate cancer detection applications ( 5 ) , which indicates that reproducibility can be attained when this is the goal of the study. This effort involves six centers where the same experimental conditions, methodology, and types of equipment are being used to generate the type of data that is representative of how reproducible a given process is. Although bias and reproducibility will continue to be a major issue when using any diagnostic platform in which the identities of the peaks are unknown, we anticipate that the underlying identities will eventually be elucidated -in fact, some peaks have been identifi ed ( 6 ) . The transition from an information profi le derived from unknown identities to a profi le derived from identifi ed and characterized molecules should minimize bias and increase reproducibility because the measurement of the markers should then be independent of the platform.
Refocusing Attention on the Biological Content
We hope that the claims by Baggerly et al. ( 1 ) do not divert attention away from the tremendous promise that proteomics holds for biomarker discovery and the accelerating scientifi c progress in this infant fi eld. In the late 1990s, our laboratory used mass spectrometry profi ling applications to determine whether tissue cell lysates obtained with laser capture microdissection contained a proteomic portrait that could discriminate different tumor types, differences between primary and metastatic disease tissue, or differences between early-stage premalignant lesions and invasive cancers ( 7 ) . The results of these and other later studies ( 8 ) indicated that there were important differences in the proteomic fi ngerprints of the tumor cells themselves, especially in the low-molecular-weight range (mass-to-charge ratio of less than 40 000). The next question at that time was, " How much of this new information can be captured from a blood sample? "
We ( 9 ) and Lay and colleagues ( 10 ) indicated that it was possible to combine mass spectral data with pattern recognition methodology to identify fi ngerprints that could discriminate among bacterial species without prior knowledge of the molecules themselves. Using a variety of different pattern recognition methods, high-throughput mass spectrometry, and serum/plasma from patients with a variety of disease states, we and others ( 5 , 6 , 11 -21 ) have generated data that appear to indicate that discriminatory information can be found within the specifi c study sets tested. Results of these independent studies appear to support the initial hypothesis that the circulatory proteome is indeed a rich source of biomarker information, even though the identity of the underpinning molecules was not known ahead of time.
This new information archive (i.e., the circulatory proteome) is being explored actively by essentially two complementary but independent approaches. One approach uses the fi ngerprints, or patterns, of mass spectral information as the diagnostic tool and does not require or use the identity or sequence of the molecules contributing to the mass spectra. These investigators are examining collections of mass spectral amplitude values and then evaluating whether the combined relative intensities of the m/z values can be used to classify disease states accurately. The alternative approach is to sequence the proteins in the new set of candidate biomarkers directly. After a candidate biomarker is identifi ed, the capture reagents (e.g., antibodies) are developed to measure multiplexed analyte panels of subsets of the candidate biomarkers. Both of these approaches have substantial advantages, disadvantages, and obstacles ahead. It is not clear which approach will have the earliest clinical impact. Our opinion is that both approaches should be applied concomitantly because any method that might provide a clinical benefi t warrants rigorous and serious investigation ( 4 ) .
What are the impediments facing investigators choosing between these approaches? The impediment facing an approach based on patterns of unidentifi ed molecules is reproducibility across platforms, time, and laboratories. Because mass spectrometry platforms are in a constant state of technologic evolution, with new, improved systems coming online every year, the scientifi c community has not yet adopted a common platform or standard operating procedure. Lack of agreement on the utilization and type of reference standards further complicates this issue. Because the molecules that underpin the pattern are not known, another impediment is the diffi culty of assuring that experimental bias is not a contributor to the discrimination. Experimental bias can result from differences in how the case and control specimens are collected and processed or from the procedure and process of generating the mass spectra itself. In addition to the problems of experimental bias, investigators must recognize the further challenges presented by high-dimensional data analysis. Rigorous validation with blinded study sets is absolutely required to guard against overfi tting. Nevertheless, mass spectrometry profi ling remains an attractive and very rapid analytical approach that is well suited for commercialization. This discovery-based approach does not require the lengthy development and validation of antibody reagents and immunoassay-based systems.
In contrast to direct mass spectrometry profi ling of blood or tissue, sequencing and characterization of the underlying constituents are a very laborious process. In fact, the cycle time for protein sequencing, characterization, antibody (or analyte-specifi c ligand) development, validation in clinical research study sets, and immunoassay development is the biggest impediment to the direct characterization approaches. The advantage of this approach is that, for characterized biomarkers, reproducibility of analyte measurements with well-tested and validated immunoassay platforms is not an issue. In addition, when the molecules are identifi ed, bias and overfi tting can be assessed directly.
Because of the need to identify the biomarkers, our research efforts have centered on identifying and sequencing the underlying discriminatory information that exists in the mass range profi led by direct mass spectrometry profi ling. Recently, we have discovered that many of the low-molecular-weight fragments with molecular information that exist in circulation are bound to high-abundance carrier proteins, such as albumin and immunoglobulins ( 22 , 23 ) . By harvesting these carrier proteins with fragments bound, the concentration of these fragments is amplifi ed to a level that is detectable by mass spectrometry and assessable by traditional immunoassays ( 24 ) . We can now take advantage of the carrier protein binding as an in vivo analytical fractionation step and selectively procure and directly sequence the bound biomarker fragments. When we use this method with serum obtained from women with ovarian cancer at either stage I or stages III-IV or from women with a high risk of ovarian cancer, who were monitored for 5 years after serum collection, and then compare the differential sequenced protein fragments found in the three sets, a complex and rich source of candidate biomarkers is revealed ( Table 1 and Fig. 1 ). To increase confi dence in the fi ndings, each of the example candidates was found iteratively with multiple peptide hits for each entity. This same information archive, in a complex fashion, appears to underpin serum mass spectral profi les. Thus, a list of sequenceidentifi ed proteins or peptides that reside in the mass range of a mass spectral profi le contributes information between profi lebased approaches and multiplexed immunoassay-based systems. Such associations, we believe, should expedite the clinical translation of this knowledge, independent of the analytical method used. Moreover, as soon as previously unidentifi ed peaks in a mass spectral pattern have been identifi ed, investigators will be better prepared to evaluate the infl uence of experimental bias.
Lessons Learned and a Plea for Better Communication
It is our opinion that it is incumbent upon those investigators who are analyzing Web-posted scientifi c data (e.g., gene microarray or mass spectral data) to evaluate the information fairly and to include the data producers in the evaluation. Close communication between the data analysts and data producers will be a necessary and integral nexus if optimal clinical benefi t is to be achieved. Without such communication, frankly, we can see no reason why investigators would want to post preliminary and ongoing experimental data on a website, not accompanying a publication, simply to have it analyzed in ways that may be inappropriate. This problem could actually slow down research and thus delay implementation of any clinical benefi t. This problem is refl ected in the title chosen by Baggerly et al.: " Signal in Noise: Evaluating Reported Reproducibility of Serum Proteomic Tests for Ovarian Cancer. " Whose reported reproducibility? What test? To our knowledge, there is currently no clinical or even experimental test using our Web-posted data, or the features themselves as the basis of any " test " offered for ovarian cancer detection. The title, in our opinion, appears to be potentially misleading, since the two data sets used as the basis for the Baggerly paper are experimental research study sets that were never part of any clinical " test. "
To be completely clear, many of the experiments that we conducted were designed with the goal of specifi cally identifying spectral changes and tracking those changes that resulted from deliberate changes in the protocol. These questions centered on some of the following aspects: What effect does changing the incubation parameters have on the spectra? What effect does changing the laser energy or mass spectrometry platform have on the spectra? What are the sources of variability between a nested set of defi ned serum samples from patients with a cancer and plasma sera from unaffected control subjects? The fi eld itself is still in its early infancy, with every laboratory using its own internal methods, mass spectrometry instruments, chemistries, and processes. Consequently, the fi eld is not yet ready to address the clinical reproducibility of this approach under guidelines such as those from the Clinical and Laboratory Standards Institute. Investigators are still refi ning their methodology to evaluate the effect of process on spectral quality, complexity, and stability. To move the fi eld forward productively, we urge that effort be directed toward the following general goals: determination of appropriate reference material, the identifi cation of well-controlled and handled sample study sets or the prospective collection of defi ned clinical study sets, and the development of standardized mass spectrometry and multiplexed immunoassay platforms and standardized operating procedures. Only after standardization should the community develop appropriate methods to assess reproducibility. The proteomics community is well poised to work together in this fashion as it methodically optimizes and evaluates various biomarker measurement and detection systems.
